2020
Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era
Li D, Mastaglia F, Fletcher S, Wilton S. Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era. Medicinal Research Reviews 2020, 40: 2650-2681. PMID: 32767426, PMCID: PMC7589267, DOI: 10.1002/med.21718.Peer-Reviewed Original ResearchConceptsNucleic acid therapeuticsPathogenesis of PDMolecular pathogenesisTargeted gene sequencingDownstream molecular eventsStratify PD patientsSmall interfering RNATargeting critical elementsParkinson's diseaseShort hairpin RNANucleic acid compoundsGene sequencesBlood-brain barrierMolecular pathogenesis of PDPrecision medicine eraDisease-modifying therapiesReduced life expectancyModify disease progressionPD clinical trialsGenetic pathogenesisNucleic acid oligomersHairpin RNAMolecular eventsMolecular therapiesClinical trials
2012
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response
Sangodkar J, Dhawan N, Melville H, Singh V, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, Burstein D, Zhang D, Politi K, DiFeo A, Narla G. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. Journal Of Clinical Investigation 2012, 122: 2637-2651. PMID: 22653055, PMCID: PMC3386822, DOI: 10.1172/jci62058.Peer-Reviewed Original ResearchMeSH KeywordsActive Transport, Cell NucleusAdenocarcinomaAdenocarcinoma of LungAnimalsAntineoplastic AgentsCell Line, TumorDrug Resistance, NeoplasmDrug SynergismEnzyme ActivationErbB ReceptorsErlotinib HydrochlorideFemaleForkhead Box Protein O1Forkhead Transcription FactorsGene Expression Regulation, NeoplasticHumansKruppel-Like Factor 6Kruppel-Like Transcription FactorsLung NeoplasmsMiceMice, Inbred BALB CMice, NudeMutationProto-Oncogene ProteinsProto-Oncogene Proteins c-aktQuinazolinesReal-Time Polymerase Chain ReactionSignal TransductionTranscription, GeneticTrifluoperazineTumor BurdenXenograft Model Antitumor AssaysConceptsAnti-EGFR-based therapyEGFR SignalingKruppel-like factor 6Lung adenocarcinomaForkhead box O1Xenograft models of lung adenocarcinomaModel of lung adenocarcinomaMetastatic lung adenocarcinomaTreat advanced cancersMolecular drivers of disease progressionDrivers of disease progressionOncogenic EGFR signalingActivation of Akt signalingFoxO1 nuclear exportTreating resistant diseaseIn vivo modelsCell culturesErlotinib resistanceResistant diseaseTreatment responseMolecular therapiesXenograft modelFDA-approved drugsDisease progressionEGFR activation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply